This could have been violated for some subjects, because use of an nsNSAID without gastroprotection is
relatively contraindicated after UGIB. By truncating follow-up at the time of UGIB, we observed that the IRRs changed in
magnitude for some drugs. We used a change of 10% of the initial estimate as an arbitrary cutoff to quantify the magnitude of
the change.